SCHEMBL10272282

SCHEMBL10272282

O=C(O)c1ccc(NC(=O)c2cc(Cl)ccc2O)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX1 P51575 10/20 0.79
TMPRSS4 Q9NRS4 8/20 0.75
P2RX4 Q99571 5/20 0.68
P2RX7 Q99572 5/20 0.68
KCNMA1 Q12791 3/20 0.67
NHERF1 O14745 1/20 0.60
MEN1 O00255 1/20 0.58
IKBKB O14920 1/20 0.58
CHUK O15111 1/20 0.58
KDR P35968 1/20 0.58
FLT3 P36888 1/20 0.58
KMT2A Q03164 1/20 0.58
MYLK Q15746 1/20 0.58
MAP4K5 Q9Y4K4 1/20 0.58
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
F2 P00734 1/20 0.57
F10 P00742 1/20 0.57
PLG P00747 1/20 0.57
PLAU P00749 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2169619 0.89 P2RX1 (1.00) P2RX1TMPRSS4P2RX4P2RX7KCNMA1
SCHEMBL29454776 0.89 P2RX1 (1.00) P2RX1TMPRSS4P2RX4P2RX7KCNMA1
SCHEMBL18341403 0.88 TMPRSS4 (0.86) P2RX1TMPRSS4P2RX4P2RX7KCNMA1
SCHEMBL13812568 0.87 TMPRSS4 (0.78) P2RX1TMPRSS4P2RX4P2RX7KCNMA1
SCHEMBL18341409 0.87 P2RX1 (0.77) P2RX1TMPRSS4P2RX4P2RX7KCNMA1
SCHEMBL18341044 0.87 P2RX1 (0.77) P2RX1TMPRSS4P2RX4P2RX7KCNMA1
SCHEMBL20601659 0.86 HDAC8 (0.67) P2RX1TMPRSS4NHERF1MEN1KMT2A
SCHEMBL538439 0.86 TMPRSS4 (1.00) P2RX1TMPRSS4P2RX4P2RX7KCNMA1
SCHEMBL24438716 0.86 P2RX1 (0.87) P2RX1TMPRSS4P2RX4P2RX7KCNMA1
SCHEMBL30692659 0.86 P2RX1 (0.87) P2RX1TMPRSS4P2RX4P2RX7KCNMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230406831-A1 COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS THE TRUSTEES OF INDIANA UNIVERSITY 2023-12-21 US disclosed
EP-4243799-A1 COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS The Trustees of Indiana University (US) 2023-09-20 EP disclosed
WO-2022103572-A1 COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS THE TRUSTEES OF INDIANA UNIVERSITY (US) 2022-05-19 WO disclosed
WO-2022103572-A1 COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS THE TRUSTEES OF INDIANA UNIVERSITY (US) 2022-05-19 WO disclosed
US-20190328687-A1 Antibacterial Compounds VICTORIA LINK LIMITED (NZ) 2019-10-31 US disclosed
WO-2016080846-A1 ANTIBACTERIAL COMPOUNDS COPP JANINE NAOMI (NZ) 2016-05-26 WO disclosed
US-8148328-B2 Salicylanilides enhance oral delivery of therapeutic peptides THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-04-03 US disclosed
US-20090163408-A1 SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163408-A1 SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES DNPEP, NGLY1, VIP P2RX1 3156/4885TMPRSS4 65/4885P2RX4 2925/4885
US-20230406831-A1 COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS HSP90B1, HSPBP1, HSP90AB1 P2RX1 4633/4885TMPRSS4 3530/4885P2RX4 4679/4885
US-20190328687-A1 Antibacterial Compounds SHARPIN, FDPS, BROX P2RX1 2514/4885TMPRSS4 1670/4885P2RX4 3421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.